| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
CPT targets the adenosine A1 receptor. It acts as a potent and selective antagonist, binding to the receptor and preventing its activation by endogenous adenosine. It shows high selectivity for the A1 receptor over the A2 receptor, with a Ki of 10.9 nM for A1 and 1440 nM for A2. This selectivity makes it a valuable tool for studying the specific functions of the A1 receptor.
|
|---|---|
| ln Vitro |
In vitro, CPT is a potent and selective antagonist of the adenosine A1 receptor. It binds to the A1 receptor with high affinity (Ki = 10.9 nM) and shows much lower affinity for the A2 receptor (Ki = 1440 nM). This selectivity allows researchers to study A1 receptor-mediated effects without significant interference from A2 receptor activity.
|
| ln Vivo |
In vivo, CPT is used as a pharmacological tool to study the role of adenosine A1 receptors in various physiological processes, including cardiovascular function, neuroprotection, and renal function. Its ability to selectively block A1 receptors makes it useful for investigating the therapeutic potential of A1 receptor antagonists in conditions such as heart failure and neurodegenerative diseases. However, specific in vivo study details are not extensively documented.
|
| Enzyme Assay |
CPT is evaluated in cell-free receptor binding assays to determine its affinity for adenosine receptors. Radioligand binding displacement assays are performed using membrane preparations expressing A1 and A2 receptors. Competition binding experiments are conducted with increasing concentrations of CPT and a fixed concentration of a labeled reference ligand. Ki values are determined to quantify the potency of receptor binding.
|
| Cell Assay |
CPT is assessed in cell-based functional assays to measure its antagonist activity at the A1 receptor. Cells expressing the A1 receptor are treated with CPT, and receptor activation is measured by assessing downstream signaling pathways, such as the inhibition of adenylyl cyclase activity. The compound's ability to block agonist-induced receptor activation is evaluated.
|
| Animal Protocol |
CPT is administered in animal models to evaluate its effects on A1 receptor-mediated functions. It has been used to study the role of A1 receptors in cardiovascular and neurological disorders. Efficacy is assessed by measuring physiological parameters such as heart rate, blood pressure, and neuroprotection. However, specific animal study protocols are not extensively documented.
|
| ADME/Pharmacokinetics |
CPT has a molecular formula of C12H16N4O2 and a molecular weight of 248.28. Its CAS number is 35873-49-5. The compound is a solid. It is soluble in DMSO. It should be stored under recommended conditions. It is also known as 8-cyclopentyl-1,3-dimethylxanthine.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is available for CPT. The compound is for research use only and is not intended for human therapeutic use. It is a selective A1 receptor antagonist used as a pharmacological tool.
|
| Additional Infomation |
8-Cyclopentyl-1,3-dimethyl-7H-purine-2,6-dione is an oxopurine.
CPT is a selective adenosine A1 receptor antagonist. It is also known as 8-cyclopentyl-1,3-dimethylxanthine. It is used in research to study the role of A1 receptors in various physiological and pathological processes. The compound is not approved for clinical use. |
| Molecular Formula |
C12H16N4O2
|
|---|---|
| Molecular Weight |
248.28104
|
| Exact Mass |
248.127
|
| CAS # |
35873-49-5
|
| PubChem CID |
1917
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.332g/cm3
|
| Boiling Point |
513.1ºC at 760mmHg
|
| Melting Point |
250-252ºC
|
| Flash Point |
264.1ºC
|
| Index of Refraction |
1.607
|
| LogP |
0.617
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
18
|
| Complexity |
380
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN1C2=C(C(=O)N(C)C1=O)N=C(C3CCCC3)N2
|
| InChi Key |
SCVHFRLUNIOSGI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H16N4O2/c1-15-10-8(11(17)16(2)12(15)18)13-9(14-10)7-5-3-4-6-7/h7H,3-6H2,1-2H3,(H,13,14)
|
| Chemical Name |
8-cyclopentyl-1,3-dimethyl-7H-purine-2,6-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~20 mg/mL (~80.55 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0277 mL | 20.1386 mL | 40.2771 mL | |
| 5 mM | 0.8055 mL | 4.0277 mL | 8.0554 mL | |
| 10 mM | 0.4028 mL | 2.0139 mL | 4.0277 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
